Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > PGX-YBG/Avenanthramide
View:
Post by prophetoffactz on Apr 29, 2024 10:30am

PGX-YBG/Avenanthramide

With the avenanthramide pill having potentially cleared 480mg at the single dose per day level now and CZO only appearing to need a 240mg twice per day level will we ultimately see a PGX-YBG/Avenanthramdie pill?

I asked Copilot what the potential health benefits are of combining avenanthramide and yeast beta glucan for treating inflammatory diseases. This is the response:


Combining avenanthramide with yeast beta glucan in the treatment of inflammatory diseases offers several potential scientific benefits:

  1. Synergistic Anti-Inflammatory Action:

    • Avenanthramide: Derived from oats, avenanthramide has demonstrated anti-inflammatory properties. It inhibits the production of pro-inflammatory molecules and modulates immune responses.
    • Yeast Beta Glucan: Yeast beta glucan is known for its immunomodulatory effects. It enhances immune function, reduces inflammation, and promotes tissue repair.
    • Benefit: Together, they may have a synergistic effect, amplifying their anti-inflammatory actions. This dual approach could lead to better disease management.
  2. Enhanced Bioavailability:

    • Avenanthramide: Bioavailability (how much of a substance reaches the bloodstream) is crucial for therapeutic efficacy.
    • Yeast Beta Glucan: As a carrier, yeast beta glucan can improve avenanthramide’s solubility and absorption.
    • Benefit: Enhanced bioavailability ensures that avenanthramide reaches its target tissues effectively.
  3. Gut Health and Immune Modulation:

    • Avenanthramide: The gut plays a key role in inflammation. Avenanthramide may positively influence gut microbiota.
    • Yeast Beta Glucan: It interacts with gut immune cells, promoting a balanced immune response.
    • Benefit: Combining them could enhance gut health and overall immune function.
  4. Cardiovascular Protection:

    • Avenanthramide: Cardiovascular diseases often involve inflammation. Avenanthramide may protect against endothelial dysfunction and atherosclerosis.
    • Yeast Beta Glucan: It has cardiovascular benefits, including cholesterol reduction.
    • Benefit: Their combined effects may mitigate cardiovascular risk factors.
  5. Wound Healing and Tissue Repair:

    • Avenanthramide: It promotes tissue repair and wound healing.
    • Yeast Beta Glucan: Known for wound-healing properties.
    • Benefit: Together, they could accelerate tissue regeneration.
  6. Immunomodulation without Overstimulation:

    • Avenanthramide: Balances immune responses.
    • Yeast Beta Glucan: Enhances immune function without excessive activation.
    • Benefit: Avenanthramide and yeast beta glucan may modulate immunity effectively without causing hyperinflammation.

In summary, this combination holds promise for managing inflammatory diseases by addressing multiple pathways and optimizing therapeutic outcomes.

Comment by prophetoffactz on Apr 29, 2024 10:31am
Food Chem         . 2024 Aug 1:448:139062.  doi: 10.1016/j.foodchem.2024.139062. Epub 2024 Mar 20. Yeast cell wall capsules for delivery of oat biomarker avenanthramide-C Linyang He 1, Yubo Zhu 1,  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities